IMR Press / CEOG / Volume 39 / Issue 4 / pii/1630475829355-1128206495

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Fertility in women survivors of hematological malignancies: what is the real role of GnRH analogue treatment?
Show Less
1 Clinic of Obstetrics and Gynecology
2 Clinic of Hematology and Bone Marrow Transplantation
3 Department of Surgery Teaching Hospital “SM della Misericordia”, Udine (Italy)
Clin. Exp. Obstet. Gynecol. 2012, 39(4), 504–508;
Published: 10 December 2012
Abstract

Purpose of investigation: The aim of this study was to evaluate the ovarian function in women who received or not gonadotropinreleasing hormone (GnRH) analogue co-treatment compared to the control group that did not receive it. Materials and Methods: This study analyzed 124 patients affected by hematological diseases between 1998 and 2007. The data were analyzed using R (v 2.9.1). Results: In the women treated with GnRH analogue, the authors found 33% post-treatment secondary amenorrhea and 6% had a pregnancy post-treatment, while in the other group the prevalence were respectively 49% and 4% (p n.s.). Moreover, in multivariate analysis the authors found bone marrow transplantation to be a risk factor for secondary amenorrhea, while the association of chemotherapy with radiotherapy was a protective factor (p < 0.05). Finally, none of the considered factors were predictive of pregnancy achievement post-treatment. Conclusions: The authors found no statistical evidence to support that Gn-RH analogue treatment preserves ovarian follicular reserve during hematologic cancer treatment, but more evidence must be obtained.
Keywords
Fertility
Hematologic disease
GnRH analogue treatment
Share
Back to top